Joshua L Bonkowsky1, Jacob Wilkes2. 1. University of Utah School of Medicine; Primary Children's Hospital, 7061Intermountain Healthcare, Salt Lake City, Utah, USA. 2. 7061Intermountain Healthcare, Salt Lake City, Utah, USA.
Abstract
OBJECTIVES: Cerebral X-linked adrenoleukodystrophy (cALD) is an inflammatory demyelination of the brain that can lead to death unless treated by hematopoietic stem cell transplantation. Survival and improved outcomes for cerebral adrenoleukodystrophy are associated with hematopoietic stem cell transplantation at earliest evidence of disease on magnetic resonance imaging (MRI). Our goal was to determine average duration between diagnosis of cALD and hematopoietic stem cell transplantation. METHODS: This was a retrospective review of data of patients aged 18 years or younger, using a nationwide administrative health care database (Pediatric Health Information System), with an International Classification of Diseases, Tenth Revision (ICD-10) diagnosis of adrenoleukodystrophy. Time range was October 1, 2015, through June 30, 2021. We determined time to hematopoietic stem cell transplantation by duration between index brain MRI and a code for hematopoietic stem cell transplantation. RESULTS: We identified 27 patients with cerebral adrenoleukodystrophy. Total charges for the cohort was $53 million. Time to transplant averaged 97 days. For Hispanic patients, time to transplant was 117 days, compared with 80 days for White, non-Hispanic patients. Comparison of different hospitals showed significant variability in time to hematopoietic stem cell transplantation. DISCUSSION: We found that time to hematopoietic stem cell transplantation was >3 months for patients with cerebral adrenoleukodystrophy in the hospitals we evaluated. We noted differences in average time by race/ethnicity and by hospital. Our findings suggest opportunity to reduce time to transplant in cerebral adrenoleukodystrophy.
OBJECTIVES: Cerebral X-linked adrenoleukodystrophy (cALD) is an inflammatory demyelination of the brain that can lead to death unless treated by hematopoietic stem cell transplantation. Survival and improved outcomes for cerebral adrenoleukodystrophy are associated with hematopoietic stem cell transplantation at earliest evidence of disease on magnetic resonance imaging (MRI). Our goal was to determine average duration between diagnosis of cALD and hematopoietic stem cell transplantation. METHODS: This was a retrospective review of data of patients aged 18 years or younger, using a nationwide administrative health care database (Pediatric Health Information System), with an International Classification of Diseases, Tenth Revision (ICD-10) diagnosis of adrenoleukodystrophy. Time range was October 1, 2015, through June 30, 2021. We determined time to hematopoietic stem cell transplantation by duration between index brain MRI and a code for hematopoietic stem cell transplantation. RESULTS: We identified 27 patients with cerebral adrenoleukodystrophy. Total charges for the cohort was $53 million. Time to transplant averaged 97 days. For Hispanic patients, time to transplant was 117 days, compared with 80 days for White, non-Hispanic patients. Comparison of different hospitals showed significant variability in time to hematopoietic stem cell transplantation. DISCUSSION: We found that time to hematopoietic stem cell transplantation was >3 months for patients with cerebral adrenoleukodystrophy in the hospitals we evaluated. We noted differences in average time by race/ethnicity and by hospital. Our findings suggest opportunity to reduce time to transplant in cerebral adrenoleukodystrophy.
Authors: Abraham S Kanate; Navneet S Majhail; Bipin N Savani; Christopher Bredeson; Richard E Champlin; Stephen Crawford; Sergio A Giralt; Charles F LeMaistre; David I Marks; James L Omel; Paul J Orchard; Jeanne Palmer; Wael Saber; Paul A Veys; Paul A Carpenter; Mehdi Hamadani Journal: Biol Blood Marrow Transplant Date: 2020-03-09 Impact factor: 5.742
Authors: Charles Peters; Lawrence R Charnas; Ye Tan; Richard S Ziegler; Elsa G Shapiro; Todd DeFor; Satkiran S Grewal; Paul J Orchard; Susan L Abel; Anne I Goldman; Norma K C Ramsay; Kathryn E Dusenbery; Daniel J Loes; Lawrence A Lockman; Shunichi Kato; Patrick R Aubourg; Hugo W Moser; William Krivit Journal: Blood Date: 2004-04-08 Impact factor: 22.113
Authors: Jennifer R Marin; Jonathan Rodean; Matt Hall; Elizabeth R Alpern; Paul L Aronson; Pradip P Chaudhari; Eyal Cohen; Stephen B Freedman; Rustin B Morse; Alon Peltz; Margaret Samuels-Kalow; Samir S Shah; Harold K Simon; Mark I Neuman Journal: JAMA Netw Open Date: 2021-01-04
Authors: Jörn-Sven Kühl; Jana Kupper; Hermann Baqué; Wolfram Ebell; Jutta Gärtner; Christoph Korenke; Birgit Spors; Ingo G Steffen; Gabriele Strauss; Sebastian Voigt; Bernhard Weschke; Almuth Weddige; Wolfgang Köhler; Robert Steinfeld Journal: JAMA Netw Open Date: 2018-07-06